Background
==========

Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death worldwide \[[@b1-medscimonit-26-e921782]\]. The incidence of HCC has increased in Western countries in the last decade \[[@b2-medscimonit-26-e921782]\]. Moreover, it is expected to increase rapidly because of infections with hepatitis viruses and due to alcohol abuse \[[@b3-medscimonit-26-e921782]\]. With improvements in diagnosis, the incidence of early-stage HCC has greatly increased.

Surgery provides favorable treatment outcomes for early-stage HCC patients \[[@b3-medscimonit-26-e921782]\]. Unfortunately, some early-stage HCC patients are contraindicated for surgery due to comorbid conditions, insufficient remnant liver after surgery, and high-risk anatomic location \[[@b4-medscimonit-26-e921782]\]. Radiofrequency ablation (RFA) is an alternative therapeutic option for early-stage HCC, which offers treatment outcomes similar to those from surgery \[[@b5-medscimonit-26-e921782]\]. To date, surgery and RFA are the main treatment options for patients with early-stage HCC \[[@b5-medscimonit-26-e921782]\]. However, it is unclear which therapy provides better outcomes for early-stage HCC patients. Our study aimed to assess and compare survival after surgery or RFA for early-stage HCC.

Material and Methods
====================

Patients
--------

HCC patients were identified from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2015. Inclusion criteria were as follows: (1) pathology-confirmed HCC (International Classification of Diseases for Oncology, 3^rd^ Edition \[ICD-O-3\] code 8170); (2) first-line treatment was either surgery (SEER code: 20--26, 30, 36--38, 50--52, 59, 60, 66, and 90) or RFA (SEER code: 16); (3) a single tumor measuring 31--50 mm; and (4) age ≥18 years. Exclusion criteria were: (1) macroscopic vascular invasion or metastasis, and (2) survival time \< 30 days. Clinical variables, including age, sex, race, marital status, tumor grade, and alpha-fetoprotein (AFP) levels, were extracted from the SEER database.

Treatment and endpoints
-----------------------

Patients were divided into the surgery group and the RFA group. The primary endpoint was overall survival (OS), defined as the time interval from diagnosis to death attributed to any cause. The secondary endpoint was cancer-specific survival (CSS), defined as the time interval from diagnosis to death because of HCC.

Statistical analyses
--------------------

We assessed the clinical variables for any significant difference between the 2 groups. Age was compared using the *t* test. Race, sex, marital status, tumor grade, and AFP levels were compared using Fisher's exact test or chi-square test. We estimated survival using the Kaplan-Meier method and compared the 2 groups statistically using the log rank test. To assess the simultaneous impact of potential confounders, Cox proportional hazards regression analysis was performed.

Selection bias existed in this retrospective study due to unbalanced baseline characteristics. A matched case-control analysis was performed to reduce the influence of selection bias on the efficacy comparison between RFA and surgery using propensity score matching (PSM). A logistic regression model was established, with treatment as the dependent variable. Patients were matched using a greedy nearest neighbor matching algorithm at 1: 1 fixed ratio. The absolute value \<0.1 was used to compare the similarity of the 2 groups, which indicated that these covariates were well balanced in the 2 groups.

Using the mice package in R, multiple imputations were performed to identify the complete set of patients for regression analysis. Different bootstrap resamples were used for each imputation by fitting a flexible parametric additive regression model on a sample with replacement from the original data. This model was conducted to predict all of the original missing and non-missing values for the target variable for the current imputation. Five sets of complete data were generated for regression analysis.

We constructed a multivariable Fine-Gray model to estimate sub-distribution hazard ratios (sdHRs). The rates of HCC-related and non-HCC-related death were evaluated using Fine and Gray multivariate regression models. R software (version 3.4.4) and SPSS 24.0 for Windows (SPSS, Chicago, IL, USA) were used to perform statistical analyses. Two-tailed *p*\<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

Our study assessed the data of 97 118 HCC patients extracted from the SEER database from 2004 to 2015. Eventually, 839 patients were included based on the inclusion and exclusion criteria. Among the 839 patients, 339 (40.41%) were treated with RFA and 500 (59.59%) with surgery. [Table 1](#t1-medscimonit-26-e921782){ref-type="table"} shows the patients' characteristics before PSM and after PSM. Before PSM, the AFP levels were higher in the RFA group, while patients were more likely to be classified as having moderately differentiated tumor grade in the surgery group. After PSM, the clinical variables were well balanced between the 2 groups.

Survival analysis in the original data
--------------------------------------

The median follow-up times of the RFA and surgery groups were 28 months (interquartile range \[IQR\]: 14--52) and 34 months (IQR: 15--59), respectively, before matching. After matching, the median follow-up times were 28 months (IQR: 14--55) for the RFA group and 33 months (IQR: 16--60) for the surgery group.

In the unmatched cohort, surgery improved the 5-year OS (59.18% *vs.* 29.35%, *p*\<0.01) ([Figure 1](#f1-medscimonit-26-e921782){ref-type="fig"}) and CSS (67.53% *vs.* 36.25%, *p*\<0.01) ([Figure 2](#f2-medscimonit-26-e921782){ref-type="fig"}) compared with RFA. In the propensity-matched cohort, surgery also had a better 5-year OS (63.95% *vs.* 37.13%, *p*\<0.01) ([Figure 3](#f3-medscimonit-26-e921782){ref-type="fig"}) and a more favorable CSS (64.01% *vs.* 38.29%, *p*\<0.01) ([Figure 4](#f4-medscimonit-26-e921782){ref-type="fig"}) than RFA. In the multivariate analysis, surgery was still an independent prognostic factor for OS (*p*\<0.001) and CSS (*p*\<0.001) ([Table 2](#t2-medscimonit-26-e921782){ref-type="table"}).

In the matched cohort, surgery also revealed a more favorable OS (HR=0.569, 95% CI: 0.396--0.743; *p*\<0.01) and a more favorable CSS (HR=0.576, 95% CI: 0.379--0.773; *p*\<0.01) compared with RFA ([Table 3](#t3-medscimonit-26-e921782){ref-type="table"}).

Survival analysis after multiple imputations
--------------------------------------------

After multiple imputations, 5 sets of complete data were generated. [Table 4](#t4-medscimonit-26-e921782){ref-type="table"} shows the results of univariate and multivariable analyses of prognostic factors. After adjusting for confounding factors, surgery revealed a better OS (HR=0.561, 95% CI: 0.420--0.702; *p*\<0.01) and a better CSS (HR=0.552, 95% CI: 0.291--0.712; *p*\<0.01) compared with RFA in multivariate analysis.

Furthermore, Fine and Gray multivariate regression models revealed that, compared with RFA, surgery had a better survival in the unmatched cohort with an adjusted sdHR of 0.689 (95% CI, 0.562--0.868; *p*=0.001) and in the propensity-matched cohort with an adjusted sdHR of 0.642 (95% CI, 0.514--0.801; *p*\<0.001) ([Table 5](#t5-medscimonit-26-e921782){ref-type="table"}).

Discussion
==========

The incidence of HCC is rising in developed countries because of alcohol abuse, and in developing countries because of hepatitis B virus infection \[[@b2-medscimonit-26-e921782]\]. Because of the poor treatment outcomes for advanced-stage HCC, mortality rates for HCC increased faster than those for any other cancer \[[@b1-medscimonit-26-e921782]\]. In contrast, survival in early-stage HCC improved. The 5-year OS of this subgroup of patients ranged from 32% to 70%, varying greatly between studies \[[@b6-medscimonit-26-e921782],[@b7-medscimonit-26-e921782]\]. However, the proportion of early-stage HCC has increased because of the development of screening programs for early-stage HCC and improvement of imaging technology \[[@b1-medscimonit-26-e921782]\]. Thus, it is important to identify the best treatment option for early-stage HCC.

HCC tumors measuring 31--50 mm are very important in clinical practice, because many patients are diagnosed at this size of the tumor \[[@b8-medscimonit-26-e921782],[@b9-medscimonit-26-e921782]\]. Although a cut-off value below 30 mm was recommended for RFA by the Americas Hepato-Pancreato-Biliary Association \[[@b10-medscimonit-26-e921782]\] and the Barcelona Clinic Liver Cancer (BCLC) staging algorithm \[[@b11-medscimonit-26-e921782]\], some reports have revealed that tumors measuring 31--50 mm could be safely ablated \[[@b12-medscimonit-26-e921782],[@b13-medscimonit-26-e921782]\]. Regarding tumors measuring 31--50 mm, some studies reported that OS was worse following RFA compared to that after surgery \[[@b14-medscimonit-26-e921782]--[@b16-medscimonit-26-e921782]\]. However, several studies showed conflicting results that RFA provided similar outcomes compared with surgery \[[@b9-medscimonit-26-e921782],[@b12-medscimonit-26-e921782],[@b17-medscimonit-26-e921782]--[@b19-medscimonit-26-e921782]\]. Our study revealed that surgery improved OS and CSS compared to RFA for HCC with a single tumor measuring 31--50 mm from the SEER database. Thus, surgery might be a better therapeutic option for early-stage HCC.

However, RFA becomes the first-line therapy for patients with BCLC stages 0--A who are not suitable for surgery and for patients with significant underlying parenchymal disease \[[@b20-medscimonit-26-e921782],[@b21-medscimonit-26-e921782]\]. Moreover, RFA is widely used as first-line therapy for early-stage HCC, especially in Asia \[[@b22-medscimonit-26-e921782]\]. Possible explanations for this phenomenon may be: (1) several studies reported that RFA provided similar OS compared with surgery \[[@b9-medscimonit-26-e921782],[@b12-medscimonit-26-e921782],[@b17-medscimonit-26-e921782]--[@b19-medscimonit-26-e921782]\], while RFA provides a better quality of life and less morbidity \[[@b15-medscimonit-26-e921782],[@b17-medscimonit-26-e921782],[@b23-medscimonit-26-e921782]\]; and (2) HCC patients in high-incidence regions are more likely to be hepatitis B virus-positive. Hepatitis B virus-positive patients are more likely to have significant underlying parenchymal disease, like severe cirrhosis and liver dysfunction. The morbidity might increase in patients with a diseased liver following surgery \[[@b24-medscimonit-26-e921782]\].

This study has certain methodological advantages compared to previous studies \[[@b14-medscimonit-26-e921782],[@b16-medscimonit-26-e921782]\]. We used PSM to reduce selection bias in the original data. Moreover, multiple imputations were performed to create 5 sets of complete data. Finally, a multivariable Fine-Gray model was used to assess the rates of HCC-related and non-HCC-related death. These methodological advantages can provide a more credible result.

However, there were some limitations in our study. First, liver function and fibrosis were not assessed. The missing data regarding liver function and fibrosis might lead to biases. Patients with severe cirrhosis were more likely to receive RFA than surgery \[[@b16-medscimonit-26-e921782]\]. As a result, patients who received RFA might have worse OS and CSS compared to patients who underwent surgery. Unfortunately, data regarding liver function and fibrosis were not recorded for many patients in the SEER database, so these data were not included in statistical analyses. To control this bias, our study generated 5 sets of complete data for regression analysis, which was conducted to predict all of the original missing and non-missing data values regarding liver function and fibrosis. Moreover, we performed PSM to control for potential biases, including age, sex, race, marital status, tumor grade, and AFP levels. The results revealed that RFA showed worse OS and CSS compared to surgery. Thus, the missing data regarding liver function and fibrosis might not have influenced the main conclusion of our study.

Furthermore, data regarding tumor recurrence were not available because of the limitations of the SEER database. The impact of surgery or RFA on local-regional-free survival and distant metastasis-free survival could not be assessed. Thus, whether the unfavorable OS and CSS of RFA were due to the higher tumor recurrence remains unclear. The answer to this question is important for deciding treatment options for patients with early-stage HCC in clinical practice. We are going to conduct a prospective cohort study to investigate the efficacy of RFA in recurrence-free survival for early-stage HCC. We hope the results will provide useful evidence on the associations between OS and recurrence-free survival.

Conclusions
===========

Surgery might be more appropriate than RFA for early-stage HCC patients with a single tumor measuring 31--50 mm. Due to the limitations of the SEER database, these results should be verified in a prospective randomized controlled trial.
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###### 

Patients characteristics in the unmatched and propensity-matched cohorts.

                               The unmatched cohort   The propensity-matched cohort (1: 1)                                         
  ---------------------------- ---------------------- -------------------------------------- ------- -------------- -------------- ---------
  Age (years)                                                                                0.129                                 \<0.001
   ≤65                         186 (54.87%)           306 (61.20%)                                   136 (59.91%)   136 (59.91%)   
   \>65                        153 (45.13%)           194 (38.80%)                                   91 (40.09%)    91 (40.09%)    
  Sex                                                                                        0.058                                 0.062
   Male                        260 (76.70%)           371 (74.20%)                                   176 (77.53%)   168 (74.00%)   
   Female                      79 (23.30%)            129 (25.80%)                                   51 (22.47%)    59 (26.00%)    
  Race                                                                                       0.181                                 0.091
   White                       201 (59.29%)           261 (52.20%)                                   131 (57.71%)   148 (65.20%)   
   Black                       43 (12.68%)            59 (11.80%)                                    28 (12.33%)    14 (6.17%)     
   Others                      95 (28.03%)            180 (36.00%)                                   68 (29.96%)    65 (28.63%)    
  Marital status                                                                             0.096                                 0.021
   Married                     203 (59.88%)           302 (60.40%)                                   133 (58.59%)   131 (57.71%)   
   Unmarried                   130 (38.35%)           182 (36.40%)                                   89 (39.21%)    86 (37.88%)    
   Unknown                     6 (1.77%)              16 (3.20%)                                     5 (2.20%)      10 (4.41%)     
  Tumor grade                                                                                0.896                                 0.063
   Well differentiated         98 (28.91%)            111 (22.20%)                                   71 (31.28%)    75 (33.04%)    
   Moderately differentiated   86 (25.37%)            258 (51.60%)                                   86 (37.89%)    84 (37.00%)    
   Poorly differentiated       32 (9.44%)             86 (17.20%)                                    30 (13.22%)    30 (13.22%)    
   Undifferentiated            2 (0.59%)              8 (1.60%)                                      2 (0.88%)      3 (1.32%)      
   Unknown                     121 (35.69%)           37 (7.40%)                                     38 (16.73%)    35 (15.42%)    
  AFP                                                                                        0.241                                 0.055
   Positive                    184 (54.28%)           225 (45.00%)                                   125 (55.07%)   119 (52.42%)   
   Negative                    102 (30.09%)           152 (30.40%)                                   68 (29.96%)    73 (32.16%)    
   Unknown                     53(15.63%)             123 (24.60%)                                   34 (14.97%)    35 (15.42%)    

###### 

Univariate and multivariable analyses of prognostic factors in the unmatched cohort.

                                                                                    Overall survival       Cancer-specific survival                                                                                            
  --------------------------------------------------------------------------------- ---------------------- -------------------------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  Age (years)                                                                                                                                                                                                                  
   ≤65[\*](#tfn2-medscimonit-26-e921782){ref-type="table-fn"} *vs*. \>65            1.358 (1.218--1.498)   \<0.001                    1.507 (1.344--1.671)   \<0.001   1.344 (1.184--1.504)   \<0.001   1.364 (1.137--1.592)   0.007
  Gender                                                                                                                                                                                                                       
   Female[\*](#tfn2-medscimonit-26-e921782){ref-type="table-fn"} *vs.* Male         1.119 (0.960--1.278)   0.167                                                       1.134 (0.951--1.317)   0.176                            
  Race                                                                                                                                                                                                                         
   White                                                                            Reference                                         Reference                        Reference                        Reference              
   Black                                                                            1.157 (0.956--1.357)   0.154                      1.078 (0.847--1.308)   0.524     1.137 (0.905--1.369)   0.275     1.068 (0.739--1.396)   0.695
   Others                                                                           0.589 (0.424--0.755)   \<0.001                    0.610 (0.419--0.800)   \<0.001   0.614 (0.426--0.801)   \<0.001   0.617 (0.352--0.882)   \<0.001
  Marital status                                                                                                                                                                                                               
   Married[\*](#tfn2-medscimonit-26-e921782){ref-type="table-fn"} *vs.* unmarried   1.303 (1.164--1.443)   \<0.001                    1.276 (1.116--1.436)   0.003     1.357 (1.197--1.516)   \<0.001   1.357 (1.132--1.582)   0.007
  Tumor grade                                                                                                                                                                                                                  
   Well differentiated                                                              Reference                                                                          Reference                        Reference              
   Moderately differentiated                                                        0.784 (0.624--1.012)   0.056                                                       0.789 (0.578--0.998)   0.027     0.864 (0.618--1.110)   0.245
   Poorly differentiated                                                            1.058 (0.817--1.299)   0.646                                                       1.262 (0.993--1.530)   0.089     1.219 (0.901--1.537)   0.222
   Undifferentiated                                                                 1.915 (0.823--2.842)   0.071                                                       2.697 (1.986--3.408)   0.006     2.191 (1.287--3.095)   0.013
  AFP                                                                                                                                                                                                                          
   Negative[\*](#tfn2-medscimonit-26-e921782){ref-type="table-fn"} *vs.* positive   1.404 (1.241--1.567)   \<0.001                    1.448 (1.279--1.617)   \<0.001   1.533 (1.343--1.722)   \<0.001   1.513 (1.275--1.751)   \<0.001
  Therapy                                                                                                                                                                                                                      
   RFA[\*](#tfn2-medscimonit-26-e921782){ref-type="table-fn"} *vs.* surgery         0.544 (0.405--0.684)   \<0.001                    0.582 (0.422--0.743)   \<0.001   0.538 (0.379--0.698)   \<0.001   0.659 (0.440--0.878)   \<0.001

RFA -- radiofrequency ablation; AFP -- alpha-fetoprotein; HR -- hazard ratio; CI -- confidence interval.

Represents reference.

###### 

Univariate analysis of prognostic factors in the propensity-matched cohort.

                                                                                    Overall survival       Cancer-specific survival                          
  --------------------------------------------------------------------------------- ---------------------- -------------------------- ---------------------- ---------
  Age                                                                                                                                                        
   ≤65[\*](#tfn4-medscimonit-26-e921782){ref-type="table-fn"} *vs.* \>65            1.377 (1.204--1.550)   \<0.001                    1.361 (1.164--1.557)   0.002
  Sex                                                                                                                                                        
   Female[\*](#tfn4-medscimonit-26-e921782){ref-type="table-fn"} *vs.* Male         1.077 (0.882--1.272)   0.455                      1.132 (0.908--1.356)   0.277
  Race                                                                                                                                                       
   White                                                                            Reference                                         Reference              
   Black                                                                            1.040 (0.791--1.290)   0.756                      1.121 (0.843--1.400)   0.420
   Others                                                                           0.616 (0.412--0.820)   \<0.001                    0.655 (0.425--0.884)   \<0.001
  Marital status                                                                                                                                             
   Married[\*](#tfn4-medscimonit-26-e921782){ref-type="table-fn"} *vs.* unmarried   1.206 (1.033--1.379)   0.034                      1.251 (1.055--1.447)   0.025
  Grade                                                                                                                                                      
   Well differentiated                                                              Reference                                         Reference              
   Moderately differentiated                                                        0.875 (0.671--1.079)   0.200                      0.917 (0.680--1.155)   0.479
   Poorly differentiated                                                            1.104 (0.820--1.389)   0.495                      1.280 (0.961--1.599)   0.129
   Undifferentiated                                                                 1.565 (0.423--2.707)   0.442                      2.183 (1.037--3.329)   0.002
  AFP                                                                                                                                                        
   Negative[\*](#tfn4-medscimonit-26-e921782){ref-type="table-fn"} *vs.* positive   1.317 (1.117--1.517)   0.007                      1.437 (1.206--1.668)   0.002
  Therapy                                                                                                                                                    
   RFA[\*](#tfn4-medscimonit-26-e921782){ref-type="table-fn"} *vs.* surgery         0.569 (0.396--0.743)   \<0.001                    0.576 (0.379--0.773)   \<0.001

RFA -- radiofrequency ablation; AFP -- alpha-fetoprotein; HR -- hazard ratio; CI -- confidence interval.

Represents reference.

###### 

Univariate and multivariable analyses of prognostic factors after multiple imputations.

                                                                                    Overall survival       Cancer-specific survival                                                                                            
  --------------------------------------------------------------------------------- ---------------------- -------------------------- ---------------------- --------- ---------------------- --------- ---------------------- ---------
  Age (years)                                                                                                                                                                                                                  
   ≤65[\*](#tfn6-medscimonit-26-e921782){ref-type="table-fn"} *vs*. \>65            1.358 (1.219--1.497)   \<0.001                    1.449 (1.306--1.592)   \<0.001   1.344 (1.184--1.505)   \<0.001   1.428 (1.263--1.592)   \<0.001
  Gender                                                                                                                                                                                                                       
   Female[\*](#tfn6-medscimonit-26-e921782){ref-type="table-fn"} *vs.* Male         1.119 (0.960--1.277)   0.167                                                       1.134 (0.952--1.317)   0.177                            
  Race                                                                                                                                                                                                                         
   White                                                                            Reference                                         Reference                        Reference                        Reference              
   Black                                                                            1.159 (0.956--1.360)   0.153                      1.101 (0.898--1.306)   0.351     1.139 (0.906--1.372)   0.272     1.062 (0.827--1.297)   0.618
   Others                                                                           0.591 (0.426--0.756)   \<0.001                    0.594 (0.423--0.764)   \<0.001   0.616 (0.428--0.804)   \<0.001   0.620 (0.426--0.814)   \<0.001
  Marital status                                                                                                                                                                                                               
   Married[\*](#tfn6-medscimonit-26-e921782){ref-type="table-fn"} *vs.* unmarried   1.301 (1.162--1.440)   \<0.001                    1.139 (0.996--1.282)   0.075     1.353 (1.194--1.511)   \<0.001   1.192 (1.028--1.357)   0.036
  Tumor grade                                                                                                                                                                                                                  
   Well differentiated                                                              Reference                                                                          Reference                                               
   Moderately differentiated                                                        0.825 (0.633--1.017)   0.056                                                       0.854 (0.623--1.085)   0.185                            
   Poorly differentiated                                                            1.009 (0.764--2.280)   0.946                                                       1.195 (0.928--1.461)   0.196                            
   Undifferentiated                                                                 1.467 (0.653--2.280)   0.361                                                       2.024 (1.199--2.849)   0.100                            
  AFP                                                                                                                                                                                                                          
   Negative[\*](#tfn6-medscimonit-26-e921782){ref-type="table-fn"} *vs.* positive   1.354 (1.187--1.521)   0.001                      1.365 (1.200--1.529)   \<0.001   1.467 (1.280--1.653)   \<0.001   1.478 (1.292--1.664)   \<0.001
  Therapy                                                                                                                                                                                                                      
   RFA[\*](#tfn6-medscimonit-26-e921782){ref-type="table-fn"} *vs.* surgery         0.544 (0.405--0.684)   \<0.001                    0.561 (0.420--0.702)   \<0.001   0.538 (0.380--0.697)   \<0.001   0.552 (0.291--0.712)   \<0.001

RFA -- radiofrequency ablation; AFP -- alpha-fetoprotein; HR -- hazard ratio; CI -- confidence interval.

Represents reference.

###### 

Univariate and multivariable analyses of prognostic factors based on the competing risk model.

                                                                                    The unmatched cohort   The propensity-matched cohort (1: 1)                                                                                          
  --------------------------------------------------------------------------------- ---------------------- -------------------------------------- ---------------------- ------- ---------------------- --------- ---------------------- ---------
  Age (years)                                                                                                                                                                                                                            
   ≤65[\*](#tfn8-medscimonit-26-e921782){ref-type="table-fn"} *vs*. \>65            1.290 (1.100--1.510)   0.002                                  1.291 (1.025--1.625)   0.030   1.300 (1.070--1.580)   0.008     1.377 (1.091--1.737)   0.007
  Gender                                                                                                                                                                                                                                 
   Female[\*](#tfn8-medscimonit-26-e921782){ref-type="table-fn"} *vs.* Male         1.120 (0.890--1.350)   0.210                                                                 1.140 (0.913--1.430)   0.250                            
  Race                                                                                                                                                                                                                                   
   White                                                                            Reference                                                     Reference                      Reference                        Reference              
   Black                                                                            1.091 (0.867--1.372)   0.460                                  0.997 (0.722--1.378)   0.990   1.134 (0.868--1.481)   0.360     0.911 (0.662--1.253)   0.570
   Others                                                                           0.662 (0.551--0.796)   \<0.001                                0.667 (0.512--0.868)   0.002   0.711 (0.566--0.894)   0.004     0.666 (0.512--0.867)   0.003
  Marital status                                                                                                                                                                                                                         
   Married[\*](#tfn8-medscimonit-26-e921782){ref-type="table-fn"} *vs.* unmarried   1.320 (1.130--1.550)   \<0.001                                1.361 (1.088--1.704)   0.007   1.230 (1.020--1.500)   0.033     1.389 (1.112--1.736)   0.004
  Tumor grade                                                                                                                                                                                                                            
   Well differentiated                                                              Reference                                                     Reference                      Reference                                               
   Moderately differentiated                                                        0.810 (0.657--0.998)   0.047                                  0.893 (0.698--1.142)   0.370   0.941 (0.745--1.190)   0.610                            
   Poorly differentiated                                                            1.300 (0.992--1.710)   0.057                                  1.251 (0.908--1.722)   0.170   1.304 (0.944--1.800)   0.110                            
   Undifferentiated                                                                 2.920 (1.364--6.234)   0.006                                  2.402 (0.945--6.105)   0.066   2.362 (0.941--5.930)   0.067                            
  AFP                                                                                                                                                                                                                                    
   Negative[\*](#tfn8-medscimonit-26-e921782){ref-type="table-fn"} *vs.* positive   1.490 (1.240--1.800)   \<0.001                                1.439 (1.136--1.823)   0.003   1.410 (1.120--1.770)   0.003     1.535 (1.207--1.953)   \<0.001
  Therapy                                                                                                                                                                                                                                
   RFA[\*](#tfn8-medscimonit-26-e921782){ref-type="table-fn"} *vs.* surgery         0.582 (0.497--0.681)   \<0.001                                0.698 (0.562--0.868)   0.001   0.623 (0.514--0.757)   \<0.001   0.642 (0.514--0.801)   \<0.001

RFA -- radiofrequency ablation; AFP -- alpha-fetoprotein; HR -- hazard ratio; CI -- confidence interval.

Represents reference.
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